The imminent patent expiration of many biopharmaceutical products will produce the possibility for generic versions of these therapeutic agents (i.e. biosimilars). However, there are a number of issues that will make approval of biosimilars much more complicated than the approval of generic equivalents of conventional pharmaceuticals. These issues centre on the intrinsic complexity of biopharmaceutical agents, which are recombinant proteins in most cases, and the heterogeneity of proteins produced by different manufacturing processes (i.e. differences in host cells, purification and processing, formulation and packaging). The increased occurrence of antibody (Ab)-mediated pure red cell aplasia (PRCA) associated with a change in the formulation of one particular epoetin-a product highlights the potential for increased immunogenicity of recombinant proteins with different formulations, or those manufactured by different processes. Thus, verification of the similarity to or substitutability of biosimilars with reference innovator biopharmaceutical products will require much more than a demonstration of pharmacokinetic similarity, which is sufficient for conventional, small molecule generic agents. Regulatory requirements for the approval of biosimilars have not yet been fully established, but preliminary guidelines from the European Agency for the Evaluation of Medicinal Products (EMEA) state that the complexity of the product, the types of changes in the manufacturing process, and differences in quality, safety and efficacy must be taken into account when evaluating biosimilars. For most products, results of clinical trials demonstrating safety and efficacy are likely to be required. In addition, because of the unpredictability of the onset and incidence of immunogenicity, extended post-marketing surveillance is also important and may be required.
Introduction
Biopharmaceutical agents are medicinal products of biotechnological origin, that contain proteins derived from recombinant DNA technology and hybridoma techniques. Recombinant proteins are derived from cell lines that are maintained in long-term culture, including some that are derived from genetically engineered bacteria (e.g. Escherichia coli). Examples of biopharmaceuticals include biological proteins (e.g. cytokines, hormones and clotting factors), monoclonal antibodies (mAbs), vaccines and cell/tissue-based therapies [1] . The use of these agents has increased dramatically in recent years; it is estimated that by 2010, nearly half of all newly approved pharmaceutical agents will be of biotechnological origin [2] .
Patents for a number of approved biopharmaceutical agents will begin to expire soon (Table 1 ), which will result in an increased demand for generic versions of these agents, as well as next generation products (collectively referred to as biosimilars). For example, the patents for epoetin-a (Epogen Õ , Amgen Inc., Thousand Oaks, CA/Johnson & Johnson, New Bruswick, NJ, USA; Eprex Õ , Ortho Biotech LLC, Manati, Puerto Rico) expired in Europe in 2004 [3] , and biosimilar versions of these erythropoiesis-stimulating agents (ESAs) are likely to emerge into the market soon. These products will probably be the first biosimilars of a class of recombinant therapeutic proteins to be marketed in the European Union.
However, the development of biosimilar proteins will be much more complicated than the development of conventional generic drugs. Conventional pharmaceutical agents such as statins and benzodiazepines are small, chemically synthesized compounds with a defined molecular weight between 100 and 1000 Da that can be accurately estimated to within 1/100 Da [4] . In contrast, biopharmaceuticals such as mAbs, growth factors and cytokines are complex and heterogeneous proteins with a much higher molecular weight, commonly ranging from 18 000 to 145 000 Da. Further, the molecular weight of biopharmaceuticals can vary by as much as 1000 Da from the average because of the molecular heterogeneity of materials produced by cells that produce and secrete the products [4] . This article will discuss many of the issues involved in the development of biosimilar recombinant proteins that include regulatory approval, bioequivalence with reference products, safety and concerns of substitutability, the need for post-marketing surveillance and differences in manufacturing processes as they may impact the characteristics of biosimilars.
Issues with biosimilar therapeutic proteins

Regulatory approval
In May 2004, the European Parliament issued recommendations for the regulatory approval of biogenerics [5] . The European Agency for the Evaluation of Medicinal Products (EMEA), the lead agency for establishing marketing authorization of generic products in Europe, is considering these recommendations in establishing guidelines for the approval of biosimilar products. However, there is uncertainty regarding the type of clinical documentation required for approval. There is also a lack of uniformity among regulatory groups in different countries regarding the approval of biosimilars. For example, the lead agency for generic evaluation in the USA [the Food and Drug Administration (FDA)] has yet to publish guidelines on approval of biosimilars.
Regulatory guidelines for evaluating the bioequivalence of biopharmaceuticals were issued for Europe by the EMEA in December 2003 [6, 7] . These guidelines address clinical and quality issues related to the bioequivalence of biopharmaceuticals claiming to be biosimilars of approved products or that are produced through changes in existing manufacturing processes [6] . In both cases, the EMEA guidelines state that the manufacturer must demonstrate similar profiles of quality, safety and efficacy between a new or modified product and the reference product.
Several factors will be taken into consideration when regulators determine the extent of the preclinical and clinical trials that will be required for approval of biosimilars. These include the complexity of the molecular structure of the biopharmaceutical agent, the type of change introduced in the manufacturing process and the impact of differences on the quality, safety and efficacy of the product [7] . The EMEA recommendations emphasize that there are some situations in which satisfactory equivalence cannot be demonstrated. In these cases, a full preclinical and clinical data package will be required for approval [7] .
Because they have opposing economic interests, major drug manufacturers and biotechnology companies differ from manufacturers of biosimilars and other generic agents with respect to their stance on regulatory requirements for approval. Innovator companies believe that the current analytical methods that would be used to characterize and compare biosimilars with innovator products are inadequate to predict efficacy and safety in the absence of historical reference data (e.g. assay validation) [1, 8] . These reference data are essential for establishing comparability between batches of an innovator product or ensuring the quality, safety and efficacy of an innovator product that has undergone a manufacturing change; they are also proprietary information. Innovator companies argue that pharmacokinetic bioequivalence is not sufficient for ensuring the safety and efficacy of biosimilars at this time. Thus, full clinical trial data should be required to demonstrate quality, safety and effectiveness, until analytical methods are able to better characterize the complexity of biopharmaceuticals and establish predictive comparability. In contrast, the biosimilar manufacturers and the generics industry believe that analytical data may be sufficient to ensure the comparability of biosimilars with reference biopharmaceuticals, and preclinical bioequivalence, and that clinical studies could be reduced or even eliminated [1, 9] . Comparability does not necessitate that two products have identical attributes, but rather that (i) they are highly similar; and (ii) based on existing knowledge any differences do not predictably affect safety and efficacy. The generics industry does agree with the need for diligent pharmacovigilance given the potential for unanticipated side effects with any product.
Bioequivalence
With conventional pharmaceuticals, any two medicinal products are considered bioequivalent if they meet two criteria. First, there must be a demonstration that the generic product has the same chemical composition as the reference compound using nuclear magnetic resonance and/or mass spectroscopy techniques [10] . Secondly, the bioavailability of the generic product must be shown to be similar to that of the reference product as assessed by results of pharmacokinetic studies demonstrating an equivalent rate and extent of absorption. Bioavailability studies are typically conducted in healthy volunteers in whom the geometric means for pharmacokinetic parameters such as area under the drug plasma concentration time curve (AUC) and maximum observed plasma concentration (C max ) fall within an acceptable range (usually no more than ±20% with a 90% degree of confidence) [11] . These bioequivalence requirements make the assumption that two chemically identical products that demonstrate an identical pharmacokinetic profile will also have identical clinical effects. Thus, the randomized clinical trials conducted to demonstrate safety and efficacy that are required for the approval of innovator agents are not necessary for the approval of conventional generics.
In contrast, because biopharmaceutical agents are much more complex and heterogeneous than conventional pharmaceutics, traditional bioequivalence studies are insufficient for demonstrating the equivalence of biosimilars to their reference biopharmaceutical agent(s) [4] . Differences in the molecular characteristics between biopharmaceutical products in the same therapeutic class have the potential to influence or alter their biological activity and immunogenic potential. Complex proteins also often have multiple sites of action, and actual or surrogate markers of efficacy are often not clearly established. Another problem is the undefined relationship between the pharmacodynamics of biopharmaceuticals and their clinical effect. Further, the analytical methods for accurate prediction of the biological, clinical and immunological properties of a biopharmaceutical agent are often lacking or insufficient [10] . Table 2 summarizes many of the potential difficulties associated with conducting bioequivalence studies with biosimilars.
Safety and efficacy
As stated by the Committee for Proprietary Medicinal Products (CPMP), comparability exercises are geared to demonstrate that the biosimilar product is similar to the reference product in terms of quality, safety and efficacy [6, 12] . To ensure that these goals are met, numerous studies should be conducted that include specification of the test material (quality) and preclinical safety tests including pharmacodynamics/ pharmacokinetics, animal models for dosage and route of administration, toxicology, immunogenicity, carcinogenesis/genotoxicity and local tolerance. There should be reproducible quality of manufacture, including comparisons of several production batches using the same manufacturing process. Preclinical and toxicological data should be provided if such studies were relevant for the original product. Finally, comparative human clinical efficacy and safety data may be required for every potential indication, with emphasis on the immunogenicity of the biosimilar. Decisions on the need to perform clinical studies with biosimilars are made on a case-by-case basis [6] .
Immunogenicity
In addition to the factors commonly associated with safety, immunogenicity is a major concern in the development of biosimilars. For example, many patients treated with recombinant interferons (IFNs) produce neutralizing Abs that significantly inhibit their biological activity [13] [14] [15] . Development of pegylated thromobopoietin (megakaryocyte growth and development factor; MGDF) was stopped in clinical trials because of treatment-associated thrombocytopenia in 13 of 325 healthy volunteers [16] . Contributing to a product's potential immunogenicity is the presence of 'altered form' species or minor contaminants that can elicit immune responses. For any specific protein, the amount of 'altered form' that is necessary to elicit a safety concern such as immunogenicity is unknown [4] . Further complicating this picture is the lack of validated animal models for evaluating the immunogenicity of proteins. The concern regarding immunogenicity of therapeutic proteins is highlighted by the recent increase in the number of cases of Ab-mediated pure red cell aplasia (PRCA) associated with one specific formulation of epoetin-a (Eprex Õ ; Ortho Biotech LLC, Manati, Puerto Rico) distributed outside of the USA [17] . This immunological form of PRCA is associated with the production of erythropoietin-neutralizing Abs that are elicited by an undefined immune response to exogenous epoetin, administered to patients with anaemia from chronic kidney disease (CKD) [18] . Although the exact immunological mechanism responsible for the increased number of cases of PRCA associated with epoetin-a is not clear, it appears to be related to changes in product formulation. The formulation of Eprex Õ in Europe was changed in 1998 when the human serum albumin stabilizer was replaced by polysorbate 80 and glycine [19] . This formulation change temporally coincided with the subsequent surge in reported cases of PRCA. However, the contribution of different stabilizers to the observed immunogenicity of epoetin-a is unclear because some other ESAs contain polysorbate 80 stabilizer, and use of these products is associated only with a very low and stable rate of PRCA [19] .
The recent EMEA/CPMP guidelines on comparability of biosimilars state that preclinical data may be insufficient to demonstrate immunogenic safety (i.e. non-immunogenicity) of some biosimilar products [6] . In these cases, the immunological safety of a biosimilar product can only be demonstrated in cohorts of patients enrolled in clinical trials and from postmarketing surveillance. Immunological safety studies also rely on the availability of highly sensitive, validated assays for measuring Abs [6] . There is also an urgent need to standardize the assays to enable the comparison of results obtained from different laboratories. Until then, only data obtained from the same laboratory can be compared.
Post-marketing surveillance
In situations where pre-marketing evaluations cannot fully establish the safety of biosimilars, post-marketing surveillance studies are likely to be required. Guidelines from the EMEA state that a pharmacovigilance plan for post-marketing monitoring should be included in the data package submitted for product approval [6] . In particular, this surveillance will help assess the immunogenicity of the individual biopharmaceutical agent. Because of the unpredictable onset and incidence of immunogenicity, post-marketing surveillance should be performed at pre-determined intervals for at least 1 year after approval of the product.
Manufacturing
The manufacturing processes for biopharmaceuticals are very complex, involving numerous steps in the production cascade. Consequently, the characteristics of the end-product can be influenced at any single step in the production cascade. For example, the nine major steps in the manufacture of proteins derived from mammalian cell culture described by Molowa and Mazanet include [20] , in order from raw materials to end-product, genetic engineering, expression systems, optimization of growth conditions for cells, batch culture design, purification, protein analyses, formulation and testing, aseptic filling and packaging. The greater complexity of manufacturing biopharmaceuticals than conventional drugs is illustrated further by comparison of the number of required analytical steps for interferon-a-2b (Intron-A Õ ) (n ¼ 244 tests) and the synthetic growth hormone levothyroxine (Unithroid Õ ) (n ¼ 67 tests) [4] . As a result of the complexity in manufacturing of biopharmaceuticals, there are a number of production issues that can affect bioequivalence of biosimilar products [21] . These issues are especially pertinent to large-scale manufacture of proteins following initial clinical results with investigational batches of a particular biopharmaceutical agent. The important production issues include consistency between production batches, stability/storage conditions and required or empirically determined changes in the manufacturing process. Assurance of product quality is provided by careful monitoring of process parameters and understanding of how these parameters affect the endproduct. For example, the culturing of cell lines from which the recombinant proteins are derived is a particularly important component of manufacturing. Culturing and maintaining viable cell lines that produce defined amounts and quality of proteins is difficult and complex, and requires controlled manipulation of many critical physical and chemical conditions.
It remains to be determined how product manufacturing can be tailored to minimize the immunogenic potential of biosimilars. It is possible that there are identifiable surrogate markers by which immunogenicity of a protein can be determined accurately at the pre-marketing stage or following a change in product formulation. However, such markers have yet to be identified for biopharmaceutical products for which biosimilar versions are being developed.
Are biosimilars comparable with innovator products?
The intrinsic heterogeneity of biopharmaceuticals has the potential to affect therapeutic efficacy. Unlike conventional pharmaceuticals, therapeutic proteins cannot be characterized completely by physiochemical methods or bioassay. Further, the relationship between physiochemical and biological properties is often unclear. While some heterogeneity of biopharmaceuticals is normal and not clinically significant, variability has been shown to produce differences in pharmacological properties. For example, differences in glycosylation between epoetin-a and epoetin-b iv34appear to be at least partially responsible for the observed differences in bioactivity between these two molecules [22] .
Even when biosimilars are developed using the same recombinant genetic constructs, host cells and culture conditions, downstream processing and purification, and formulation and packaging, there is no guarantee of bioequivalence or substitutability with reference products. Innovator companies employ unique and proprietary techniques that may affect the efficacy and safety of a product. For example, there are six companies that manufacture the recombinant human growth hormone, somatotropin. All of these available products have 191 amino acids, no carbohydrate residues and possess a molecular weight of 22 000 Da. Despite the similarities in composition, these six products are metabolized at different rates, with elimination half-lives ranging from 1.75 h with Saizen Õ (Serono Inc., Rockland, MA) to 7-10 h for Norditropin Õ (Novo Nordisk Pharmaceuticals Inc., Princeton, NJ) [4] . Thus, no two versions of even the oldest and simplest biopharmaceutic products are truly bioequivalent. Dissimilarities among available preparations of epoetin-a have also been demonstrated by Schellekens and colleagues. These investigators showed that products manufactured in Asia, India and South America are heterogenous with respect to the molecular isoforms of epoetin that they contain (Figure 1 ) [23] .
One of the problems with quality assurance assays for biopharmaceuticals is that they are generally less sensitive and precise than are tests for small molecules. Assays for small molecule impurities (e.g. mass spectroscopy) are sensitive in the 1:10 000-1:200 000 range, whereas the physiochemical assays used more often for biopharmaceuticals (e.g. gel electrophoresis, bioassays) are less sensitive for detecting minor molecular forms (generally <1:1000) [24] . Bioassay precision is typically low for biopharmaceuticals, with interassay variations of 15% considered good. For these reasons, the impurities in biopharmaceuticals (up to 2% of material) are difficult to analyse. Computer algorithms can help in the design of less immunogenic proteins, but no single technique can unequivocally predict immunogenicity of a particular protein [25] . In addition, results from animal studies may not accurately reflect the potential immune response to a protein in patients. To minimize the risk to patients, immune responses to any recombinant protein should be evaluated using sensitive and relevant assays at all stages of development.
The stability of biopharmaceuticals is another concern. Small molecules tend to follow Arrhenius behaviour (i.e. thermally dependent molecular motion) and thus have predictable stability based on acceleration studies. In contrast, stability for biopharmaceuticals is harder to predict because proteins degrade by many different pathways [21] . Slight variations in the manufacturing process that may affect protein stability are not necessarily identifiable using accelerated stability studies. For example, degradation of deglycosylated erythropoietin at 70 C occurs faster than for the native, fully glycosylated molecule [26] .
Conclusions
The development of biosimilars is far more complicated than for conventional generic agents, and consequently their approval is likely to require much more than the demonstration of pharmacokinetic bioequivalence. 
Follow-on biologics iv35
In the post-PRCA era, the immunogenicity of recombinant therapeutic proteins has become a major safety concern. The situation is complicated further by the complexities of manufacturing and establishing standard process parameters, testing for quality assurance, and packaging and distribution. As manufacturing and clinical experience with the first biosimilar products accumulates, existing approval guidelines for biosimilars established by the EMEA or other regulatory bodies (e.g. FDA) may be amended-and new guidelines written-to include newly developed or improved methods for analysis of product characteristics, algorithms for predicting immunogenicity, assays for measuring patients' immune response and improved production methods. Given the wide variability in types and characteristics of different biopharmaceutical agents, these guidelines are likely to be agent specific.
